Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Their project, called Phytogene, harnesses the power of “biopharming” — a method that transforms plants into living drug ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Eli Lilly and Company (NYSE:LLY) offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of March 20. It is one of the best dividend stocks on our list as the company has ...

The issuer is solely responsible for the content of this announcement.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.